This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain

• Sponsor: Boehringer Ingelheim (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03993119
• Collaborator: (none)
• Enrollment: 500
• Locations: 45
• Actual Duration (Months): 12.7
• Patients Per Site: 11.1
• Patients Per Site Per Month: 0.9

Study Details

Study Description

Brief Summary

This is an observational, multicenter and cross-sectional study in Non-valvular atrial fibrillation (NVAF) elderly patients currently on Non-vitamin K antagonist oral anticoagulant (NOAC) treatment for their stroke prevention.

Condition or Disease	Intervention/Treatment	Phase
Atrial Fibrillation	Drug: Non-vitamin K antagonist oral anticoagulant

Study Design

• Study Type: Observational
• Actual Enrollment: 500 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Non-Interventional, Cross-sectional Study to Describe NOACs Management in Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) in Spain.
• Actual Study Start Date: Jul 30, 2019
• Actual Primary Completion Date: Aug 20, 2020
• Actual Study Completion Date: Aug 20, 2020

Arms and Interventions

Arm	Intervention/Treatment
patients with NVAF	Drug: Non-vitamin K antagonist oral anticoagulant; Non-vitamin K antagonist oral anticoagulant

Outcome Measures

Primary Outcome Measures

1. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex [At the single study visit (Day 1).]

   Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to sex is reported.

2. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Sex [At the single study visit (Day 1).]

   Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to sex is reported.

3. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Age (Categorical) [At the single study visit (Day 1).]

   Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' age is reported.

4. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Patient's Age (Categorical) [At the single study visit (Day 1).]

   Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patient's age (categorical) is reported.

5. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to a Prior Diagnosis of Heart Failure [At the single study visit (Day 1).]

   Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to a prior diagnosis of heart failure is reported.

6. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to a Prior Diagnosis of Heart Failure [At the single study visit (Day 1).]

   Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to a prior diagnosis of heart failure is reported.

7. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Coronary Artery Disease [At the single study visit (Day 1).]

   Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the study visit according to patients' coronary artery disease is reported.

8. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Coronary Artery Disease [At the single study visit (Day 1).]

   Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' coronary artery disease is reported.

9. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Diabetes [At the single study visit (Day 1).]

   Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' diabetes is reported.

10. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Diabetes [At the single study visit (Day 1).]

    Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' diabetes is reported.

11. Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Chronic Kidney Disease [At the single study visit (Day 1).]

    Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' chronic kidney disease is reported.

12. Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Chronic Kidney Disease [At the single study visit (Day 1).]

    Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' chronic kidney disease is reported.

Secondary Outcome Measures

1. Serum Creatinine Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Serum creatinine concentration from the last available blood sample analysis was retrieved from patients' medical records. Serum creatinine concentration from the last available blood sample analysis according to current NOAC type is reported.

2. Creatinine Clearance From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients' medical records were used to retrieve the creatinine clearance (CrCl). These results were directly collected in the Electronic Case Report Form (eCRF). In cases where CrCl was not available in patients's medical record but serum creatinine was available, CrCl was estimated using Cockcroft-Gault formula: CrCl = (140 - Age(years)) x Weight (kilogram) x [0.85 if female] / 72 x [Serum Creatinine (milligram/deciliterL)] Reported are Crcl values which are calculated according to: Cockcroft-Gault formula and CrCl values directly collected in the eCRF Cockcroft-Gault formula only Directly collected in the eCRF

3. Number of Participants in Each Category of Creatinine Clearance Range From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients' medical records were used to retrieve the creatinine clearance (CrCl). These results were directly collected in the Electronic Case Report Form (eCRF). In cases where CrCl was not available in patients' medical record but serum creatinine was available, CrCl was estimated using Cockcroft-Gault formula: CrCl = (140 - Age(years)) x Weight (kilogram) x [0.85 if female] / 72 x [Serum Creatinine (milligram/deciliterL)] The number of participants for each of the following creatinine clearance (CrCl) ranges is reported: CrCl ≥90: Kidney damage with normal or increased glomerular filtration rate (GFR) CrCl 60-89: Kidney damage with mild decreased GFR CrCl 30-59: Moderate decrease in GFR CrCl 15-29: Severe decrease in GFR CrCl <15: Kidney failure

4. Aspartate Aminotransferase (AST) Concentration From the Last Available Blood Sample According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients' medical records were used to retrieve AST concentration. AST concentration from the last available blood sample according to non-vitamin K antagonist oral anticoagulant (NOAC) type is reported.

5. Alanine Aminotransferase (ALT) From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients's medical records were used to retrieve ALT concentration. ALT concentration from the last available blood sample according to NOAC type is reported.

6. Bilirubin Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients's medical records were used to retrieve bilirubin concentration. Bilirubin concentration from the last available blood sample according to NOAC type is reported.Results from the last available blood sample analysis from patients' medical records were used to retrieve bilirubin concentration. Bilirubin concentration from the last available blood sample according to NOAC type is reported.

7. Haemoglobin Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients' medical records were used to retrieve haemoglobin concentration. Haemoglobin concentration from the last available blood sample according to NOAC type is reported.

8. Platelet Levels From the Last Available Blood Sample According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients's medical records were used to retrieve platelet levels. Platelet levels from the last available blood sample according to NOAC type is reported.

9. Number of Patients in Each Category of Serum Creatinine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin, Hemoglobin and Platelet Levels According to Current Non-vitamin K Antagonist Oral (NOAC) Type [At the single study visit (Day 1).]

   Results from the last available blood sample analysis from patients' medical records were used to retrieve serum creatinine, ALT, AST, bilirubin, hemoglobin concentration and platelet levels. For each reported laboratory parameter the values were categorized in two categories: Serum creatinine: Normal value : 0.6-1.2 mg/dl in males and 0.5-1.1 mg/dl in females High/low value ALT: Normal values: 7-55 units per liter (UI/L) High/low values AST: Normal values: 8-48 UI/L High/low values Bilirubin: Normal values: 0.2-1.2 milligram per deciliter (mg/dl) High/low values Haemoglobin: Normal values: 12-18 gram/deciliter (g/dL) High/low values Platelets: Normal values: 150-450 x10^3/µL High/low values

10. Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Years Since NVAF Diagnosis According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (day 1).]

    The number of years since NVAF diagnosis was obtained from number of years between date of NVAF diagnosis and date of study visit. The date of NVAF diagnosis was retrieved from patient's medical records. The number of years since NVAF diagnosis and date of study visit is reported for: All patients; Patients treated previously with vitamin K antagonists (VKA); Patients treated with NOAC as first anticoagulant .

11. Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Patients in Each Category of NVAF Type According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (day 1).]

    NVAF was categorized in four categories: Persistent; Long standing persistent; Permanent; Paroxysmal.

12. Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Patients in Each Category of EHRA Scale for Atrial Fibrillation (AF) Related Symptoms According to Current NOAC Type [At the single study visit (day 1).]

    The European Heart Rhythm Association (EHRA) score of atrial fibrillation is a classification system for the extent of atrial fibrillation. It places patients in one of five categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. The EHRA categories are the following: 1-no symptoms 2a-mild symptoms; normal daily activity not affected. 2b-moderate symptoms; normal daily activity not affected. 3-severe symptoms; normal daily activity affected. 4-disabling; normal daily activity discontinued.

13. Number of Patients in Each Category of Cardioversion, Ablation, Coronary Interventions and Pacemaker Carrier According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Number of patients with (category Yes) and without (category No) cardioversion, ablation, coronary interventions and pacemaker carrier according to current NOAC type is reported.

14. Number of Patients in Each Category of Coronary Interventions According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Number of patients in each category of coronary interventions according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Coronary interventions were categorized in: Percutaneous coronary intervention and Coronary artery bypass grafting.

15. Clinical Risk Factors: Number of Patients in Each Category of Heart Failure, Coronary Artery Disease, Sleep Apnoea-hypopnoea Syndrome, Hypertension and Hyperlipidaemia According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Number of patients in each category of heart failure, coronary artery disease, sleep apnoea-hypopnoea syndrome, hypertension and hyperlipidaemia according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Heart failure, coronary artery disease, sleep apnoea-hypopnoea syndrome, hypertension and hyperlipidaemia were categorized in the following two categories: No; Yes.

16. Clinical Risk Factors: Number of Heart Failure Patients in Each Category of New York Heart Association (NYHA) Classification According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    The NYHA provides a simple way of classifying the extent of heart failure and it has 4 categories: A - No objective evidence of cardiovascular disease B - Objective evidence of minimal cardiovascular disease C - Objective evidence of moderately severe cardiovascular disease D - Objective evidence of severe cardiovascular disease Number of heart failure patients in each category of New York Heart Association (NYHA) classification according to current NOAC type is reported.

17. Clinical Risk Factors: Left Ventricular Ejection Fraction According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Left ventricular ejection fraction (LVEF) according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. LVEF was obtained from the patients' medical records.

18. Age-adjusted Charlson Comorbidity Index Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero.

19. Number of Patients With and Without the Comorbidities Included in the Charlson Comorbidity Index According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Number of patients with (Yes) and without (No) the comorbidities which were included in the Charlson Comorbidity Index according to current NOAC type is reported. The comorbidities which were included in the Charlson Comorbidity Index were the following: Myocardial infarction Congestive heart failure Peripheral vascular disease Cerebrovascular disease Dementia Chronic Obstructive Pulmonary Disease (COPD) Connective tissue disease Peptic ulcer disease Liver disease (No/Mild/Moderate to severe) Diabetes mellitus (No/Uncomplicated/End-organ damage) Hemiplegia Moderate to severe renal disease Solid Tumor (No/Localized/Metastatic) Leukaemia Lymphoma Acquired Immune Deficiency Syndrome (AIDS).

20. Number of Patients With and Without Any History of Thromboembolic Events, Number of Patients in Each Category of Different Types of Thromboembolic Events According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Reported is the number of patients in each category of: Any history of thromboembolic events Transient Ischemic Attack (TIA) Ischemic stroke Haemorrhagic stroke Embolism systemic Deep vein thrombosis Pulmonary embolism. Any history of thromboembolic events, Transient Ischemic Attack (TIA), ischemic stroke, haemorrhagic stroke, embolism systemic, deep vein thrombosis and pulmonary embolism were categorized in the following two categories: No Yes.

21. Number of Patients in Each Category of Stable Angina, Unstable Angina, Myocardial Infarction With ST Segment Elevation and Myocardial Infarction Without ST Segment Elevation According to Current NOAC Type [At the single study visit (Day 1).]

    Number of patients in each category of stable angina, unstable angina, myocardial infarction with ST segment elevation and myocardial infarction without ST segment elevation according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Stable angina, unstable angina, myocardial infarction with ST segment elevation myocardial infarction without ST segment elevation were categorized in the following 2 categories: Yes; No.

22. Total Number of Thromboembolic Events, Number of Each Type of Thromboembolic Events, Number of Stable and Unstable Anginas, and Number of ST and Non-ST Myocardial Infarction According to Current NOAC Type [At the single study visit (Day 1).]

    Total number of thromboembolic events, number of each type of thromboembolic events, number of stable and unstable anginas, and number of ST and non-ST myocardial infarction according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported.

23. Number of Patients With and Without Any History of Bleeding Events and Number of Patients in Each Category of Bleeding Type According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Number of patients with (category Yes) and without (category No) any history of bleeding events and number of patients in each category of the following bleeding types is reported: Intracranial Digestive Genitourinary Gingival Nasal Pulmonary Articular-muscular Conjunctival. Intracranial, digestive, genitourinary, gingival, nasal, pulmonary, articular-muscular, conjunctival were categorized in two categories: No Yes.

24. Total Number of Bleeding Events and Number of Each Type of Bleeding Events According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Total number of bleeding events and number of bleeding events for the following bleeding types is reported: Intracranial Digestive Genitourinary Gingival Nasal Pulmonary Articular-muscular Conjunctival.

25. CHA2DS2-VASc Total Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    The Congestive heart failure, Hypertension, Age (> 75), Diabetes mellitus, Stroke/TIA, Vascular disease, Age 65-74, Sex Category (CHA2DS2-VASc) score is a clinical prediction rule to estimate the risk of stroke in patients with Atrial Fibrillation (AF); it is frequently used to determine the need for an anticoagulation therapy, relating the high scores to a great risk of stroke and a low score corresponds to a lower risk of stroke. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.

26. Number of Patients on Each Category of CHA2DS2-VASc Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    The Congestive heart failure, Hypertension, Age (> 75), Diabetes mellitus, Stroke/TIA, Vascular disease, Age 65-74, Sex Category (CHA2DS2-VASc) total score was categorized in three categories, according to the risk of stroke: Low risk (score 0 in male; score 1 in female) Moderate risk (score 1 in male; score 2 in female) High risk (score ≥2 in male; score ≥3 in female)

27. HAS-BLED Total Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (>65 years), Drugs and Alcohol (HAS-BLED) score may range from 0 to 9 with 0 being the best outcome. The high scores indicate a greater risk of bleeding and a low score corresponds to a lower risk of bleeding.

28. Number of Patients in Each Category of HAS-BLED Score According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    The Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs and Alcohol (HAS-BLED) total score was categorized in three categories according to the bleeding risk: Low risk (score 0) Intermediate risk (score 1-2) High risk (score ≥3)

29. Number of Patients With Any Concomitant Treatments to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Number of Patients for Each Concomitant Treatment to NOAC at Study Visit According to Current NOAC Type [At the single study visit (Day 1).]

    Number of patients in each category (No;Yes) of any concomitant treatments to NOAC and number of patients in each category (No; Yes) for each concomitant treatment to NOAC at study visit according to current NOAC type is reported. The concomitant treatment to non-vitamin K antagonist oral anticoagulant (NOAC) were the following: Angiotensin-Receptor Blockers (ARB) or Angiotensin Converting Enzyme inhibitors (ACE) inhibitor Beta-blocker Calcium channel blockers Diuretics Amiodarone Statin Proton pump inhibitor H2-receptor antagonist Digoxin NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) Dronedarone Ketoconazole Cyclosporine Itraconazole Other antiarrhythmics

30. Number of Patients in Each Category of Previous Vitamin K Antagonists (VKA) Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Number of patients in each category of previous Vitamin K Antagonists (VKA) treatment according to duration since the first non-vitamin K antagonist oral anticoagulant (NOAC) initiation is reported. Previous VKA treatment was categorized in 2 categories: No; Yes.

31. Number of Patients Treated Previously With the VKA Acenocoumarol and Number of Patients Treated Previously With the VKA Warfarin According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients treated previously (before they were treated with non-vitamin K antagonist oral anticoagulant (NOAC)) with the Vitamin K Antagonists (VKA) acenocoumarol and number of patients treated previously with the VKA warfarin according to duration since the first NOAC initiation is reported.

32. Duration of Previous Vitamin K Antagonists (VKA) Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Duration of treatment (in years) is reported for: All patients treated previously with Vitamin K Antagonists (VKA) (row:All patients treated previously with VKA) Patients treated only with the VKA warfarin (row: Warfarin patients) Patients treated only with the VKA acenocoumarol (row: Acenocoumarol patients)

33. Duration Since Non-valvular Atrial Fibrillation (NVAF) Diagnosis Until First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Duration (in years) since non-valvular atrial fibrillation (NVAF) diagnosis until first NOAC initiation according to duration since the first NOAC initiation is reported for: All patients Patients treated previously with VKA Patients treated only with NOAC as anticoagulant (AC)

34. First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and First NOAC Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as first NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as first NOAC according to duration since the first NOAC initiation is reported.

35. Number of Patients Who Changed (Increased and Decreased) and Did Not Change the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who changed (increased and decreased) and did not change the first non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.

36. First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Treatment duration (in years) is reported for: Patients who stopped first NOAC treatment; Patients who did not stop the first NOAC treatment.

37. Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for first NOAC treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

38. Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for first NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

39. Number of Switches to a New Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Per Patient According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of switches to a new non-vitamin K antagonist oral anticoagulant (NOAC) per patient according to duration since the first NOAC initiation is reported.

40. Number of Patients in Each Category of Number of Switches to a New Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Per Patient According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients based on the number of switches to a new NOAC per patient according to duration since the first NOAC initiation is reported. Number of switches to a new NOAC was categorized in 3 categories: 0 switches 1 switch 2 switches.

41. Total Number of Switches According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Total number of switches according to duration since the first NOAC initiation is reported.

42. Number of Switches in Each Category of Reason for Switch According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Reason for switch was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

43. Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and Second NOAC Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as second NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as second NOAC according to duration since the first NOAC initiation is reported.

44. Number of Patients Who Changed (Increased or Decreased) and Did Not Change the Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who changed (increased or decreased) and did not change the second non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.

45. Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Second NOAC treatment duration (in years) according to duration since the first NOAC initiation is reported.

46. Number of Patients in Each Category of Reason for Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for second non-vitamin K antagonist oral anticoagulant (NOAC) treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

47. Number of Patients in Each Category of Reason for Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for second NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

48. Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and Third NOAC Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as third NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as third NOAC according to duration since the first NOAC initiation is reported.

49. Number of Patients Who Changed (Increased and Decreased) and Did Not Change the Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients who changed (increased and decreased) and did not change the third non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.

50. Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Duration of third NOAC treatment for patients who stopped NOAC treatment.

51. Number of Patients in Each Category of Reason for Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for Third NOAC treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

52. Number of Patients in Each Category of Reason for Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Reason for Third NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event

53. Duration (in Years) in Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Duration (in years) in NOAC treatment is reported for: All patients (patients who received or did not receive VKA) Patients treated previously with Vitamin K Antagonists (VKA) Patients treated with NOAC as first anticoagulant

54. Number of Patients in Each Category of Total Time in Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients in each category of total time in non-vitamin K antagonist oral anticoagulant (NOAC) treatment according to duration since the first NOAC initiation is reported. Total time in NOAC treatment was categorized in 4 categories: <1 year; 1-2 years; 2-3 years; >3 years.

55. Number of Patients for Each Type of Antiplatelet Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Number of patients for each type of following antiplatelet treatment that the patients ever received is reported: None (reports the patients who did not receive any antiplatelet treatment) Acetyl salicylic acid Clopidogrel Prasugrel Ticlopidine Ticagrelor Cilostazol Triflusal Dipyridamole Others (other antiplatelet treatment than above mentioned).

56. Number of Patients for Each Type of Antiplatelet Treatment at the Time of Study Visit According to Duration Since the First NOAC Initiation [At the single study visit (Day 1).]

    Number of patients for each of the following antiplatelet treatment types at the time of study visit according to duration since the first NOAC initiation is reported: None (reports the patients who did not receive any antiplatelet treatment) Acetyl salicylic acid Clopidogrel Prasugrel Ticlopidine Ticagrelor Cilostazol Triflusal Dipyridamole Others (other antiplatelet treatment than above mentioned).

57. Time in Treatment With Antiplatelet Agents (in Years) According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation [At the single study visit (Day 1).]

    Time in treatment with antiplatelet agents (in years) according to duration since the first NOAC initiation is reported.

58. Number of Patients in Each Score of Clinical Frailty Scale Grading at the Time of the Study Visit According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Clinical Frailty Scale (CFS) is used commonly to assess frailty. It is a 9-point scale from 1 to 9 (1=very fit; 2=well; 3=Managing well; 4=Vulnerable; 5=Mildly frail; 6=Moderately frail; 7=Severely frail; 8=very severely frail; 9=terminally ill) that summarizes the overall level of fitness or frailty of an older adult after they had been evaluated by a health care professional. Applying the CFS to patients is quick and requires data collection by watching the patient (mobilize), inquiring about their habitual physical activity and ability. A person with a score >4 was considered frail.

59. Number of Patients in Each Category Clinical Frailty Scale at the Time of the Study Visit According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type [At the single study visit (Day 1).]

    Clinical Frailty Scale (CFS) is used commonly to assess frailty. It is a 9-point scale from 1 to 9 (1=very fit; 2=well; 3=Managing well; 4=Vulnerable; 5=Mildly frail; 6=Moderately frail; 7=Severely frail; 8=very severely frail; 9=terminally ill) that summarizes the overall level of fitness or frailty of an older adult after they had been evaluated by a health care professional. Applying the CFS to patients is quick and requires data collection by watching the patient (mobilize), inquiring about their habitual physical activity and ability. CFS was categorized in two categories, according to this ranges: Frailty patients - CFS scoring >4 Non-frailty patients - CFS scoring ≤4

60. Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Usage at the Time of First NOAC Initiation According to Current NOAC Type [At the single study visit (Day 1).]

    Reason for First NOAC usage was categorized in the following two categories: Primary prevention; Secondary prevention.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 75 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients are willing and provide written informed consent prior to participate in this study

• Patients ≥ 75 years-old at the time of the study visit.

• Patients with a diagnosis of non-valvular atrial fibrillation (NVAF).

• Patients who are being treated with NOAC treatment according to the indication approved in the Summary of Product Characteristics (SmPC).

• Patients who have started the NOAC treatment at least 3 months prior to the study visit.

Exclusion Criteria:

Patients will be excluded from participating in this study if the following criterion is met:

• Current participation in any clinical trial of a drug or device.

• Patients who have any contraindication for NOAC treatment, according to the SmPC.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	H. Fundación Alcorcón	Alcorcón, Madrid		Spain	28922
2	Consulta Privada	Almería		Spain	4630
3	H. Dr. José Molina Orosa	Arrecife, Las Palmas		Spain	35500
4	Centro Médico San Juan de Dios	Barakaldo, Bizkaia		Spain	48901
5	H. Sagrat Cor	Barcelona		Spain	8029
6	H. Vall d'Hebron	Barcelona		Spain	8035
7	H. Sant Pau	Barcelona		Spain	8041
8	H. Vithas Internacional Xanit	Benalmádena, Málaga		Spain	29631
9	Ambulatorio Txurdinaga	Bilbao		Spain	48004
10	H. San Juan de Dios de Bormujos	Bormujos, Sevilla		Spain	41930
11	H. Provincial de Castellón	Castellón		Spain	12002
12	H. San Pedro Alcántara	Cáceres		Spain	10003
13	Consulta privada Dr. Ruiz	Córdoba		Spain	14006
14	H. Arquitecto Marcide	Ferrol, A Coruña		Spain	15405
15	H. de Jaen	Jaen		Spain	23007
16	H. U. de León	León		Spain	24008
17	H. Arnau de Vilanova	Lleida		Spain	25198
18	H. Lucus Augusti	Lugo		Spain	27003
19	H. La Princesa	Madrid		Spain	28006
20	Sanitas La Zarzuela	Madrid		Spain	28023
21	H. Central de la Defensa Gómez	Madrid		Spain	28047
22	H. Puerta de Hierro	Majadahonda, Madrid		Spain	28222
23	H. de Mataró	Mataró, Barcelona		Spain	8304
24	H. de Mendaro	Mendaro, Guipúzcoa		Spain	20850
25	H. Morales Meseguer	Murcia		Spain	30008
26	H. Virgen de la Arrixaca	Murcia		Spain	30120
27	Consulta Privada	Málaga		Spain	29002
28	Consulta privada Merelles Otero	Ourense		Spain	32003
29	Consulta Privada	Ourense		Spain	32003
30	H. Río Carrión	Palencia		Spain	34005
31	H. Son Llatzer	Palma de Mallorca		Spain	7198
32	H. de Navarra	Pamplona		Spain	31008
33	H. Comarcal de la Vega Baja	San Bartolomé, Alicante		Spain	3314
34	H. Moises Broggi	Sant Joan Despí, Barcelona		Spain	8970
35	H. Marqués de Valdecilla	Santander		Spain	39008
36	H. Álvarez-Buylla	Santullano, Asturias		Spain	33619
37	H. Virgen de la Macarena	Sevilla		Spain	41009
38	H. Virgen del Valle	Toledo		Spain	45071
39	H. de Torrejón	Torrejón De Ardoz, Madrid		Spain	28850
40	Consulta Privada	Valencia		Spain	46005
41	H. General de Valencia	Valencia		Spain	46014
42	Hospital La Fe	Valencia		Spain	46026
43	H. Virgen de la Concha	Zamora		Spain	49022
44	H. Clínico Lozano Blesa	Zaragoza		Spain	50009
45	H. Miguel Servet	Zaragoza		Spain	50009

Sponsors and Collaborators

• Boehringer Ingelheim

Investigators

• Study Chair: Mireia canals, ([phone], [e-mail]

Study Documents (Full-Text)

• Study Protocol - May 24, 2019
• Statistical Analysis Plan - Jul 8, 2020

More Information

Additional Information:

• Related Info

Publications

None provided.

• Responsible Party: Boehringer Ingelheim
• ClinicalTrials.gov Identifier: NCT03993119
• Other Study ID Numbers: 1160-0297
• First Posted: Jun 20, 2019
• Last Update Posted: Sep 29, 2021
• Last Verified: Sep 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Atrial Fibrillation; Anticoagulants

Study Results

Participant Flow

Recruitment Details	This was a non-Interventional, cross-sectional study to describe NOACs management in elderly patients with non-valvular atrial fibrillation (NVAF) in Spain. RE-BELD Study.
Pre-assignment Detail	All subjects were screened for eligibility prior to participation in the study. Study visit was a routine visit, one of those visits already scheduled in order to follow up the patients' NVAF (Non-Valvular Atrial Fibrillation). Patients were considered included when they agreed to participate in the study and signed the informed consent form.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Period Title: Overall Study
STARTED	192	76	166	66
COMPLETED	192	76	166	66
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban	Total
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Total of all reporting groups
Overall Participants	192	76	166	66	500
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	80.83 (4.50)	80.89 (4.64)	82.29 (4.90)	82.02 (4.80)	81.48 (4.73)
Sex: Female, Male (Count of Participants)
Female	77 40.1%	46 60.5%	94 56.6%	33 50%	250 50%
Male	115 59.9%	30 39.5%	72 43.4%	33 50%	250 50%
Race and Ethnicity Not Collected (Count of Participants)
Count of Participants [Participants]	0 0%
Weight (Kg) (Kilogram (kg)) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Kilogram (kg)]	76.33 (11.53)	73.23 (13.57)	74.63 (13.40)	71.59 (12.41)	74.52 (12.75)
Weight categorical (Count of Participants)
≤60 kg	13 6.8%	12 15.8%	23 13.9%	14 21.2%	62 12.4%
>60 kg	130 67.7%	58 76.3%	132 79.5%	49 74.2%	369 73.8%
Height (centimeter (cm)) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [centimeter (cm)]	163.86 (8.28)	160.88 (8.88)	162.64 (9.61)	162.93 (7.75)	162.77 (8.86)
Body Mass Index (kilogram/meter^2 (kg/m^2)) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [kilogram/meter^2 (kg/m^2)]	28.58 (4.06)	28.13 (4.77)	28.32 (4.71)	27.46 (3.88)	28.27 (4.42)
Body mass index categorical (BMI cat) (Count of Participants)
Underweight: BMI< 18.5 kg/m2	0 0%	0 0%	0 0%	0 0%	0 0%
Normal weight: 18.5 kg m2≤ BMI≤ 25 kg/m2	25 13%	16 21.1%	36 21.7%	12 18.2%	89 17.8%
Overweight: 25 kg/m2< BMI≤ 30 kg/m2	61 31.8%	31 40.8%	55 33.1%	21 31.8%	168 33.6%
Obese: 30 kg/m2<BMI≤ 35 kg/m2	33 17.2%	17 22.4%	33 19.9%	9 13.6%	92 18.4%
Severely Obese: BMI> 35 kg/m2	8 4.2%	3 3.9%	12 7.2%	2 3%	25 5%
Caregiver (Count of Participants)
No	93 48.4%	41 53.9%	78 47%	39 59.1%	251 50.2%
Yes	76 39.6%	30 39.5%	82 49.4%	24 36.4%	212 42.4%
Place where patient is living (Count of Participants)
Home alone	17 8.9%	19 25%	23 13.9%	10 15.2%	69 13.8%
At home with partner/other family member/a friend	147 76.6%	52 68.4%	119 71.7%	45 68.2%	363 72.6%
Other's home (e.g. family member's)	15 7.8%	1 1.3%	17 10.2%	9 13.6%	42 8.4%
Nursing home	8 4.2%	0 0%	5 3%	2 3%	15 3%
Smoking habit (Count of Participants)
Ex-smoker	66 34.4%	17 22.4%	43 25.9%	19 28.8%	145 29%
Smoker	6 3.1%	1 1.3%	4 2.4%	1 1.5%	12 2.4%
Non-smoker	111 57.8%	57 75%	116 69.9%	45 68.2%	329 65.8%
Alcohol consumption (Count of Participants)
Casual or non-consumer	149 77.6%	66 86.8%	134 80.7%	56 84.8%	405 81%
Habitual	19 9.9%	6 7.9%	13 7.8%	3 4.5%	41 8.2%
Abuse	0 0%	0 0%	1 0.6%	1 1.5%	2 0.4%
Dependence	0 0%	0 0%	0 0%	0 0%	0 0%

Outcome Measures

1. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Current NOAC Dose According to Sex
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to sex is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Sex: Male	Sex: Female
Arm/Group Description	This arm included all male patients who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all female patients who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	250	250
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	115 59.9%	77 101.3%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	30 15.6%	46 60.5%
Current NOAC: Apixaban (2.5 mg BID and 5 mg BID patients)	72 37.5%	94 123.7%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	33 17.2%	33 43.4%
Dabigatran 110 mg BID	56 29.2%	41 53.9%
Dabigatran 150 mg BID	59 30.7%	36 47.4%
Rivaroxaban 15 mg QD	8 4.2%	23 30.3%
Rivaroxaban 20 mg QD	22 11.5%	23 30.3%
Apixaban 2.5 mg BID	31 16.1%	43 56.6%
Apixaban 5 mg BID	41 21.4%	51 67.1%
Edoxaban 30 mg QD	13 6.8%	18 23.7%
Edoxaban 60 mg QD	20 10.4%	15 19.7%

2. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Sex
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to sex is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Sex: Male	Sex: Female
Arm/Group Description	This arm included all male patients who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all female patients who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	250	250
Mean (Standard Deviation) [Years]	2.43 (2.19)	2.22 (1.83)

3. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Age (Categorical)
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' age is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Age: 75-79 Years	Age: 80-84 Years	Age: ≥85 Years
Arm/Group Description	This arm included all patients aged between 75-79 years who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all patients aged between 80-84 years who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all patients ≥85 years old who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	210	152	138
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	93 48.4%	59 77.6%	40 24.1%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	34 17.7%	23 30.3%	19 11.4%
Current NOAC: Apixaban (2.5 mg BID and 5 mg BID patients)	59 30.7%	48 63.2%	59 35.5%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	24 12.5%	22 28.9%	20 12%
Dabigatran 110 mg BID	22 11.5%	39 51.3%	36 21.7%
Dabigatran 150 mg BID	71 37%	20 26.3%	4 2.4%
Rivaroxaban 15 mg QD	10 5.2%	9 11.8%	12 7.2%
Rivaroxaban 20 mg QD	24 12.5%	14 18.4%	7 4.2%
Apixaban 2.5 mg BID	16 8.3%	21 27.6%	37 22.3%
Apixaban 5 mg BID	43 22.4%	27 35.5%	22 13.3%
Edoxaban 30 mg QD	7 3.6%	11 14.5%	13 7.8%
Edoxaban 60 mg QD	17 8.9%	11 14.5%	7 4.2%

4. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Patient's Age (Categorical)
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patient's age (categorical) is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Age: 75-79 Years	Age: 80-84 Years	Age: ≥85 Years
Arm/Group Description	This arm included all patients aged between 75-79 years who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all patients aged between 80-84 years who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included all patients ≥85 years old who participated in the study and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	210	152	138
Mean (Standard Deviation) [Years]	2.33 (2.07)	2.32 (1.93)	2.32 (2.05)

5. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to a Prior Diagnosis of Heart Failure
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to a prior diagnosis of heart failure is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Heart Failure: No	Heart Failure: Yes
Arm/Group Description	This arm included patients who participated in the study and had no prior diagnosis of heart failure and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had prior diagnosis of heart failure and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	316	184
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	129 67.2%	63 82.9%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	54 28.1%	22 28.9%
Current NOAC: Apixaban (2.5 mg BID and 5 mg patients)	96 50%	70 92.1%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	37 19.3%	29 38.2%
Dabigatran 110 mg BID	63 32.8%	34 44.7%
Dabigatran 150 mg BID	66 34.4%	29 38.2%
Rivaroxaban 15 mg QD	21 10.9%	10 13.2%
Rivaroxaban 20 mg QD	33 17.2%	12 15.8%
Apixaban 2.5 mg BID	31 16.1%	43 56.6%
Apixaban 5 mg BID	65 33.9%	27 35.5%
Edoxaban 30 mg QD	16 8.3%	15 19.7%
Edoxaban 60 mg QD	21 10.9%	14 18.4%

6. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to a Prior Diagnosis of Heart Failure
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to a prior diagnosis of heart failure is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Heart Failure: No	Heart Failure: Yes
Arm/Group Description	This arm included patients who participated in the study and had no prior diagnosis of heart failure and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had prior diagnosis of heart failure and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	316	184
Mean (Standard Deviation) [Years]	2.27 (2.02)	2.41 (2.02)

7. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Coronary Artery Disease
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the study visit according to patients' coronary artery disease is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Coronary Artery Disease: No	Coronary Artery Disease: Yes
Arm/Group Description	This arm included patients who participated in the study and had no coronary artery disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had coronary artery disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	414	82
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	156 81.3%	35 46.1%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	63 32.8%	13 17.1%
Current NOAC: Apixaban (2.5 mg BID and 5 mg BID patients)	142 74%	21 27.6%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	53 27.6%	13 17.1%
Dabigatran 110 mg BID	78 40.6%	19 25%
Dabigatran 150 mg BID	78 40.6%	16 21.1%
Rivaroxaban 15 mg QD	23 12%	8 10.5%
Rivaroxaban 20 mg QD	40 20.8%	5 6.6%
Apixaban 2.5 mg BID	62 32.3%	10 13.2%
Apixaban 5 mg BID	80 41.7%	11 14.5%
Edoxaban 30 mg QD	23 12%	8 10.5%
Edoxaban 60 mg QD	30 15.6%	5 6.6%

8. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Coronary Artery Disease
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' coronary artery disease is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Coronary Artery Disease: No	Coronary Artery Disease: Yes
Arm/Group Description	This arm included patients who participated in the study and had no coronary artery disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had coronary artery disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	414	82
Mean (Standard Deviation) [Years]	2.38 (2.02)	2.04 (1.99)

9. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Diabetes
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' diabetes is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Diabetes: No	Diabetes: Yes
Arm/Group Description	This arm included patients who participated in the study and had no diabetes were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had diabetes and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	346	154
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	135 70.3%	57 75%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	51 26.6%	25 32.9%
Current NOAC: Apixaban (2.5 mg BID and 5 mg BID patients)	113 58.9%	53 69.7%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	47 24.5%	19 25%
Dabigatran 110 mg BID	68 35.4%	29 38.2%
Dabigatran 150 mg BID	67 34.9%	28 36.8%
Rivaroxaban 15 mg QD	22 11.5%	9 11.8%
Rivaroxaban 20 mg QD	29 15.1%	16 21.1%
Apixaban 2.5 mg BID	51 26.6%	23 30.3%
Apixaban 5 mg BID	62 32.3%	30 39.5%
Edoxaban 30 mg QD	21 10.9%	10 13.2%
Edoxaban 60 mg QD	26 13.5%	9 11.8%

10. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Diabetes
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' diabetes is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Diabetes: No	Diabetes: Yes
Arm/Group Description	This arm included patients who participated in the study and had no diabetes were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had diabetes and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	346	154
Mean (Standard Deviation) [Years]	2.39 (2.00)	2.17 (2.07)

11. Primary Outcome

Title	Type of Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and NOAC Dose According to Chronic Kidney Disease
Description	Number of patients receiving dabigatran (Current NOAC: Dabigatran), rivaroxaban (Current NOAC: Rivaroxaban), apixaban (Current NOAC: Apixaban), edoxaban (Current NOAC: Edoxaban), dabigatran 110 mg (twice daily) BID, dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD at the time of study visit according to patients' chronic kidney disease is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Chronic Kidney Disease: No	Chronic Kidney Disease: Yes
Arm/Group Description	This arm included patients who participated in the study and had no chronic kidney disease were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had chronic kidney disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	408	92
Current NOAC: Dabigatran (110 mg BID and 150 mg BID patients)	166 86.5%	26 34.2%
Current NOAC: Rivaroxaban (15 mg QD and 20 mg QD patients)	64 33.3%	12 15.8%
Current NOAC: Apixaban (2.5 mg BID and 5 mg BID patients)	130 67.7%	36 47.4%
Current NOAC: Edoxaban (30 mg QD and 60 mg QD patients)	48 25%	18 23.7%
Dabigatran 110 mg BID	76 39.6%	21 27.6%
Dabigatran 150 mg BID	90 46.9%	5 6.6%
Rivaroxaban 15 mg QD	19 9.9%	12 15.8%
Rivaroxaban 20mg QD	45 23.4%	0 0%
Apixaban 2.5 mg BID	43 22.4%	31 40.8%
Apixaban 5 mg BID	87 45.3%	5 6.6%
Edoxaban 30 mg QD	17 8.9%	14 18.4%
Edoxaban 60 mg QD	31 16.1%	4 5.3%

12. Primary Outcome

Title	Number of Years Since First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation to Study Visit According to Chronic Kidney Disease
Description	Number of years since first Non-vitamin K antagonist oral anticoagulant (NOAC) initiation to study visit according to patients' chronic kidney disease is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Chronic Kidney Disease: No	Chronic Kidney Disease: Yes
Arm/Group Description	This arm included patients who participated in the study and had no chronic kidney disease were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).	This arm included patients who participated in the study and had chronic kidney disease and were receiving any Non-vitamin K antagonist oral anticoagulant (NOAC) (either dabigatran, rivaroxaban, apixaban or edoxaban) for their nonvalvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC).
Measure Participants	408	92
Mean (Standard Deviation) [Years]	2.34 (2.05)	2.25 (1.89)

13. Secondary Outcome

Title	Serum Creatinine Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Serum creatinine concentration from the last available blood sample analysis was retrieved from patients' medical records. Serum creatinine concentration from the last available blood sample analysis according to current NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	159	63	122	47
Mean (Standard Deviation) [milligram/deciliter (mg/dl)]	1.00 (0.23)	1.05 (0.29)	1.15 (0.41)	1.14 (0.39)

14. Secondary Outcome

Title	Creatinine Clearance From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients' medical records were used to retrieve the creatinine clearance (CrCl). These results were directly collected in the Electronic Case Report Form (eCRF). In cases where CrCl was not available in patients's medical record but serum creatinine was available, CrCl was estimated using Cockcroft-Gault formula: CrCl = (140 - Age(years)) x Weight (kilogram) x [0.85 if female] / 72 x [Serum Creatinine (milligram/deciliterL)] Reported are Crcl values which are calculated according to: Cockcroft-Gault formula and CrCl values directly collected in the eCRF Cockcroft-Gault formula only Directly collected in the eCRF
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	141	71	156	46
CrCl calculated by Cockcroft-Gault formula and CrCl values directly collected in the eCRF	63.50 (18.49)	55.42 (17.59)	54.45 (18.65)	53.04 (18.40)
Calculated by Cockcroft-Gault formula only	62.72 (18.82)	54.59 (17.79)	53.77 (19.35)	52.83 (18.84)
Directly collected in the eCRF	66.27 (17.27)	59.98 (16.47)	56.30 (16.69)	53.59 (17.69)

15. Secondary Outcome

Title	Number of Participants in Each Category of Creatinine Clearance Range From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients' medical records were used to retrieve the creatinine clearance (CrCl). These results were directly collected in the Electronic Case Report Form (eCRF). In cases where CrCl was not available in patients' medical record but serum creatinine was available, CrCl was estimated using Cockcroft-Gault formula: CrCl = (140 - Age(years)) x Weight (kilogram) x [0.85 if female] / 72 x [Serum Creatinine (milligram/deciliterL)] The number of participants for each of the following creatinine clearance (CrCl) ranges is reported: CrCl ≥90: Kidney damage with normal or increased glomerular filtration rate (GFR) CrCl 60-89: Kidney damage with mild decreased GFR CrCl 30-59: Moderate decrease in GFR CrCl 15-29: Severe decrease in GFR CrCl <15: Kidney failure
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	141	71	156	63
<15 ml/min/1.73m^2	0 0%	0 0%	0 0%	0 0%
15-29 ml/min/1.73m^2	0 0%	3 3.9%	10 6%	7 10.6%
30-59 ml/min/1.73m^2	72 37.5%	41 53.9%	92 55.4%	37 56.1%
60-89 ml/min/1.73m^2	55 28.6%	25 32.9%	46 27.7%	18 27.3%
≥90 ml/min/1.73m^2	14 7.3%	2 2.6%	8 4.8%	1 1.5%

16. Secondary Outcome

Title	Aspartate Aminotransferase (AST) Concentration From the Last Available Blood Sample According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients' medical records were used to retrieve AST concentration. AST concentration from the last available blood sample according to non-vitamin K antagonist oral anticoagulant (NOAC) type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	128	62	138	59
Mean (Standard Deviation) [international units per liter (IU/L)]	24.13 (11.34)	21.60 (7.43)	25.57 (16.01)	20.81 (8.58)

17. Secondary Outcome

Title	Alanine Aminotransferase (ALT) From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients's medical records were used to retrieve ALT concentration. ALT concentration from the last available blood sample according to NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	127	66	143	62
Mean (Standard Deviation) [units per liter (UI/L)]	22.38 (13.66)	18.28 (8.95)	21.52 (17.81)	20.15 (20.76)

18. Secondary Outcome

Title	Bilirubin Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients's medical records were used to retrieve bilirubin concentration. Bilirubin concentration from the last available blood sample according to NOAC type is reported.Results from the last available blood sample analysis from patients' medical records were used to retrieve bilirubin concentration. Bilirubin concentration from the last available blood sample according to NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	103	53	119	45
Mean (Standard Deviation) [milligram/deciliter (mg/dl)]	0.83 (0.47)	0.79 (0.51)	0.74 (0.47)	0.75 (0.37)

19. Secondary Outcome

Title	Haemoglobin Concentration From the Last Available Blood Sample According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients' medical records were used to retrieve haemoglobin concentration. Haemoglobin concentration from the last available blood sample according to NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	181	75	165	64
Mean (Standard Deviation) [gram/deciliter (g/dl)]	13.23 (1.66)	13.37 (1.61)	12.99 (1.90)	13.17 (1.92)

20. Secondary Outcome

Title	Platelet Levels From the Last Available Blood Sample According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Results from the last available blood sample analysis from patients's medical records were used to retrieve platelet levels. Platelet levels from the last available blood sample according to NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	174	73	160	64
Mean (Standard Deviation) [x 10^3/microliter (μL)]	203.37 (60.50)	222.07 (77.13)	215.59 (81.48)	189.45 (68.80)

21. Secondary Outcome

Title	Number of Patients in Each Category of Serum Creatinine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin, Hemoglobin and Platelet Levels According to Current Non-vitamin K Antagonist Oral (NOAC) Type
Description	Results from the last available blood sample analysis from patients' medical records were used to retrieve serum creatinine, ALT, AST, bilirubin, hemoglobin concentration and platelet levels. For each reported laboratory parameter the values were categorized in two categories: Serum creatinine: Normal value : 0.6-1.2 mg/dl in males and 0.5-1.1 mg/dl in females High/low value ALT: Normal values: 7-55 units per liter (UI/L) High/low values AST: Normal values: 8-48 UI/L High/low values Bilirubin: Normal values: 0.2-1.2 milligram per deciliter (mg/dl) High/low values Haemoglobin: Normal values: 12-18 gram/deciliter (g/dL) High/low values Platelets: Normal values: 150-450 x10^3/µL High/low values
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Normal levels	132 68.8%	44 57.9%	72 43.4%	32 48.5%
High/low levels	27 14.1%	19 25%	50 30.1%	15 22.7%
Normal levels	122 63.5%	61 80.3%	127 76.5%	59 89.4%
High/low levels	6 3.1%	1 1.3%	11 6.6%	0 0%
Normal levels	121 63%	65 85.5%	133 80.1%	59 89.4%
High/low levels	6 3.1%	1 1.3%	10 6%	3 4.5%
Normal levels	91 47.4%	46 60.5%	109 65.7%	41 62.1%
High/low levels	12 6.3%	7 9.2%	10 6%	4 6.1%
Normal levels	143 74.5%	63 82.9%	121 72.9%	50 75.8%
High/low levels	38 19.8%	12 15.8%	44 26.5%	14 21.2%
Normal levels	140 72.9%	65 85.5%	128 77.1%	48 72.7%
High/low levels	34 17.7%	8 10.5%	32 19.3%	16 24.2%

22. Secondary Outcome

Title	Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Years Since NVAF Diagnosis According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The number of years since NVAF diagnosis was obtained from number of years between date of NVAF diagnosis and date of study visit. The date of NVAF diagnosis was retrieved from patient's medical records. The number of years since NVAF diagnosis and date of study visit is reported for: All patients; Patients treated previously with vitamin K antagonists (VKA); Patients treated with NOAC as first anticoagulant .
Time Frame	At the single study visit (day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	165	66
All patients	4.78 (4.26)	5.85 (4.70)	6.01 (6.54)	5.63 (4.99)
Patients treated previously with VKA	6.30 (4.59)	7.95 (4.87)	7.60 (5.43)	7.59 (4.94)
Patients treated with NOAC as first anticoagulant	2.79 (2.71)	3.52 (3.21)	3.95 (7.28)	1.72 (1.74)

23. Secondary Outcome

Title	Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Patients in Each Category of NVAF Type According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	NVAF was categorized in four categories: Persistent; Long standing persistent; Permanent; Paroxysmal.
Time Frame	At the single study visit (day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	189	71	160	63
Persistent	32 16.7%	11 14.5%	31 18.7%	12 18.2%
Long standing persistent	21 10.9%	3 3.9%	10 6%	5 7.6%
Permanent	99 51.6%	26 34.2%	66 39.8%	36 54.5%
Paroxysmal	37 19.3%	31 40.8%	53 31.9%	10 15.2%

24. Secondary Outcome

Title	Non-valvular Atrial Fibrillation (NVAF) Characteristics: Number of Patients in Each Category of EHRA Scale for Atrial Fibrillation (AF) Related Symptoms According to Current NOAC Type
Description	The European Heart Rhythm Association (EHRA) score of atrial fibrillation is a classification system for the extent of atrial fibrillation. It places patients in one of five categories based on how much they are limited during physical activity; the limitations/symptoms are in regard to normal breathing and varying degrees in shortness of breath and/or angina. The EHRA categories are the following: 1-no symptoms 2a-mild symptoms; normal daily activity not affected. 2b-moderate symptoms; normal daily activity not affected. 3-severe symptoms; normal daily activity affected. 4-disabling; normal daily activity discontinued.
Time Frame	At the single study visit (day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	188	69	157	62
1-none	47 24.5%	25 32.9%	52 31.3%	17 25.8%
2a-mild	83 43.2%	30 39.5%	70 42.2%	31 47%
2b-moderate	45 23.4%	11 14.5%	28 16.9%	11 16.7%
3-severe	10 5.2%	3 3.9%	6 3.6%	3 4.5%
4-disabling	3 1.6%	0 0%	1 0.6%	0 0%

25. Secondary Outcome

Title	Number of Patients in Each Category of Cardioversion, Ablation, Coronary Interventions and Pacemaker Carrier According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Number of patients with (category Yes) and without (category No) cardioversion, ablation, coronary interventions and pacemaker carrier according to current NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	171 89.1%	70 92.1%	151 91%	57 86.4%
Yes	16 8.3%	6 7.9%	14 8.4%	9 13.6%
No	178 92.7%	75 98.7%	160 96.4%	64 97%
Yes	11 5.7%	1 1.3%	6 3.6%	2 3%
No	167 87%	65 85.5%	148 89.2%	60 90.9%
Yes	22 11.5%	11 14.5%	17 10.2%	5 7.6%
No	166 86.5%	67 88.2%	151 91%	58 87.9%
Yes	23 12%	9 11.8%	15 9%	8 12.1%

26. Secondary Outcome

Title	Number of Patients in Each Category of Coronary Interventions According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Number of patients in each category of coronary interventions according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Coronary interventions were categorized in: Percutaneous coronary intervention and Coronary artery bypass grafting.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who underwent coronary interventions.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	22	11	17	5
Percutaneous coronary intervention	19 9.9%	9 11.8%	14 8.4%	4 6.1%
Coronary artery bypass grafting	3 1.6%	2 2.6%	3 1.8%	1 1.5%

27. Secondary Outcome

Title	Clinical Risk Factors: Number of Patients in Each Category of Heart Failure, Coronary Artery Disease, Sleep Apnoea-hypopnoea Syndrome, Hypertension and Hyperlipidaemia According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Number of patients in each category of heart failure, coronary artery disease, sleep apnoea-hypopnoea syndrome, hypertension and hyperlipidaemia according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Heart failure, coronary artery disease, sleep apnoea-hypopnoea syndrome, hypertension and hyperlipidaemia were categorized in the following two categories: No; Yes.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	129 67.2%	54 71.1%	96 57.8%	37 56.1%
Yes	63 32.8%	22 28.9%	70 42.2%	29 43.9%
No	156 81.3%	63 82.9%	142 85.5%	53 80.3%
Yes	35 18.2%	13 17.1%	21 12.7%	13 19.7%
No	170 88.5%	70 92.1%	152 91.6%	57 86.4%
Yes	19 9.9%	6 7.9%	11 6.6%	9 13.6%
No	46 24%	13 17.1%	22 13.3%	7 10.6%
Yes	146 76%	63 82.9%	144 86.7%	59 89.4%
No	76 39.6%	28 36.8%	68 41%	17 25.8%
Yes	116 60.4%	48 63.2%	97 58.4%	49 74.2%

28. Secondary Outcome

Title	Clinical Risk Factors: Number of Heart Failure Patients in Each Category of New York Heart Association (NYHA) Classification According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The NYHA provides a simple way of classifying the extent of heart failure and it has 4 categories: A - No objective evidence of cardiovascular disease B - Objective evidence of minimal cardiovascular disease C - Objective evidence of moderately severe cardiovascular disease D - Objective evidence of severe cardiovascular disease Number of heart failure patients in each category of New York Heart Association (NYHA) classification according to current NOAC type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS with heart failure. NYHA classification for heart failure patients is missing.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	61	20	61	22
A - No objective evidence of cardiovascular disease	2 1%	0 0%	3 1.8%	0 0%
B - Objective evidence of minimal cardiovascular disease	39 20.3%	12 15.8%	25 15.1%	8 12.1%
C - Objective evidence of moderately severe cardiovascular disease	18 9.4%	6 7.9%	29 17.5%	12 18.2%
D - Objective evidence of severe cardiovascular disease	2 1%	2 2.6%	4 2.4%	2 3%

29. Secondary Outcome

Title	Clinical Risk Factors: Left Ventricular Ejection Fraction According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Left ventricular ejection fraction (LVEF) according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. LVEF was obtained from the patients' medical records.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	181	58	130	57
Mean (Standard Deviation) [percent ejection fraction (%)]	59.47 (9.66)	59.43 (10.45)	58.85 (12.27)	57.91 (12.57)

30. Secondary Outcome

Title	Age-adjusted Charlson Comorbidity Index Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	75	165	66
Mean (Standard Deviation) [Score on a scale]	5.26 (1.74)	5.39 (1.63)	5.99 (2.04)	6.27 (2.41)

31. Secondary Outcome

Title	Number of Patients With and Without the Comorbidities Included in the Charlson Comorbidity Index According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Number of patients with (Yes) and without (No) the comorbidities which were included in the Charlson Comorbidity Index according to current NOAC type is reported. The comorbidities which were included in the Charlson Comorbidity Index were the following: Myocardial infarction Congestive heart failure Peripheral vascular disease Cerebrovascular disease Dementia Chronic Obstructive Pulmonary Disease (COPD) Connective tissue disease Peptic ulcer disease Liver disease (No/Mild/Moderate to severe) Diabetes mellitus (No/Uncomplicated/End-organ damage) Hemiplegia Moderate to severe renal disease Solid Tumor (No/Localized/Metastatic) Leukaemia Lymphoma Acquired Immune Deficiency Syndrome (AIDS).
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Myocardial infarction; No	176 91.7%	65 85.5%	147 88.6%	55 83.3%
Myocardial infarction; Yes	16 8.3%	11 14.5%	18 10.8%	11 16.7%
Congestive heart failure: No	129 67.2%	55 72.4%	96 57.8%	38 57.6%
Congestive heart failure: Yes	63 32.8%	21 27.6%	70 42.2%	28 42.4%
Peripheral vascular disease: No	172 89.6%	70 92.1%	151 91%	59 89.4%
Peripheral vascular disease: Yes	20 10.4%	5 6.6%	15 9%	7 10.6%
Cerebrovascular disease: No	153 79.7%	63 82.9%	133 80.1%	57 86.4%
Cerebrovascular disease: Yes	39 20.3%	13 17.1%	33 19.9%	9 13.6%
Dementia: No	188 97.9%	72 94.7%	153 92.2%	60 90.9%
Dementia: Yes	4 2.1%	4 5.3%	13 7.8%	6 9.1%
COPD: No	161 83.9%	66 86.8%	141 84.9%	54 81.8%
COPD: Yes	31 16.1%	10 13.2%	24 14.5%	12 18.2%
Connective tissue disease: No	189 98.4%	76 100%	164 98.8%	66 100%
Connective tissue disease: Yes	3 1.6%	0 0%	2 1.2%	0 0%
Peptic ulcer disease: No	187 97.4%	74 97.4%	156 94%	65 98.5%
Peptic ulcer disease: Yes	5 2.6%	2 2.6%	10 6%	1 1.5%
Liver disease: No	190 99%	74 97.4%	161 97%	65 98.5%
Liver disease: Mild	2 1%	2 2.6%	5 3%	1 1.5%
Liver disease: Moderate to severe	0 0%	0 0%	0 0%	0 0%
Diabetes mellitus: No	135 70.3%	51 67.1%	113 68.1%	47 71.2%
Diabetes mellitus: Uncomplicated	48 25%	18 23.7%	36 21.7%	11 16.7%
Diabetes mellitus: End-organ damage	9 4.7%	7 9.2%	17 10.2%	8 12.1%
Hemiplegia: No	191 99.5%	76 100%	164 98.8%	62 93.9%
Hemiplegia: Yes	1 0.5%	0 0%	2 1.2%	4 6.1%
Moderate to severe renal disease: No	166 86.5%	64 84.2%	130 78.3%	48 72.7%
Moderate to severe renal disease: Yes	26 13.5%	12 15.8%	36 21.7%	18 27.3%
Solid tumor: No	178 92.7%	69 90.8%	148 89.2%	57 86.4%
Solid tumor: Localized	13 6.8%	7 9.2%	16 9.6%	7 10.6%
Solid tumor: Metastatic	1 0.5%	0 0%	2 1.2%	2 3%
Leukaemia: No	192 100%	76 100%	166 100%	66 100%
Leukaemia: Yes	0 0%	0 0%	0 0%	0 0%
Lymphoma: No	192 100%	74 97.4%	165 99.4%	65 98.5%
Lymphoma: Yes	0 0%	2 2.6%	1 0.6%	1 1.5%
AIDS: No	192 100%	76 100%	165 99.4%	66 100%
AIDS: Yes	0 0%	0 0%	1 0.6%	0 0%

32. Secondary Outcome

Title	Number of Patients With and Without Any History of Thromboembolic Events, Number of Patients in Each Category of Different Types of Thromboembolic Events According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Reported is the number of patients in each category of: Any history of thromboembolic events Transient Ischemic Attack (TIA) Ischemic stroke Haemorrhagic stroke Embolism systemic Deep vein thrombosis Pulmonary embolism. Any history of thromboembolic events, Transient Ischemic Attack (TIA), ischemic stroke, haemorrhagic stroke, embolism systemic, deep vein thrombosis and pulmonary embolism were categorized in the following two categories: No Yes.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	153 79.7%	53 69.7%	120 72.3%	48 72.7%
Yes	39 20.3%	23 30.3%	46 27.7%	18 27.3%
No	180 93.8%	66 86.8%	155 93.4%	64 97%
Yes	10 5.2%	9 11.8%	8 4.8%	2 3%
No	173 90.1%	65 85.5%	146 88%	60 90.9%
Yes	19 9.9%	7 9.2%	20 12%	5 7.6%
No	189 98.4%	73 96.1%	163 98.2%	65 98.5%
Yes	1 0.5%	0 0%	1 0.6%	0 0%
No	191 99.5%	73 96.1%	164 98.8%	63 95.5%
Yes	0 0%	0 0%	0 0%	2 3%
No	190 99%	71 93.4%	162 97.6%	65 98.5%
Yes	1 0.5%	2 2.6%	2 1.2%	0 0%
No	190 99%	73 96.1%	161 97%	64 97%
Yes	1 0.5%	1 1.3%	3 1.8%	1 1.5%

33. Secondary Outcome

Title	Number of Patients in Each Category of Stable Angina, Unstable Angina, Myocardial Infarction With ST Segment Elevation and Myocardial Infarction Without ST Segment Elevation According to Current NOAC Type
Description	Number of patients in each category of stable angina, unstable angina, myocardial infarction with ST segment elevation and myocardial infarction without ST segment elevation according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported. Stable angina, unstable angina, myocardial infarction with ST segment elevation myocardial infarction without ST segment elevation were categorized in the following 2 categories: Yes; No.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	187 97.4%	73 96.1%	161 97%	64 97%
Yes	4 2.1%	0 0%	4 2.4%	1 1.5%
No	190 99%	72 94.7%	158 95.2%	64 97%
Yes	1 0.5%	1 1.3%	6 3.6%	1 1.5%
No	183 95.3%	65 85.5%	153 92.2%	62 93.9%
Yes	8 4.2%	8 10.5%	11 6.6%	3 4.5%
No	183 95.3%	69 90.8%	156 94%	57 86.4%
Yes	8 4.2%	4 5.3%	8 4.8%	8 12.1%

34. Secondary Outcome

Title	Total Number of Thromboembolic Events, Number of Each Type of Thromboembolic Events, Number of Stable and Unstable Anginas, and Number of ST and Non-ST Myocardial Infarction According to Current NOAC Type
Description	Total number of thromboembolic events, number of each type of thromboembolic events, number of stable and unstable anginas, and number of ST and non-ST myocardial infarction according to current non-vitamin K antagonist oral anticoagulant (NOAC) type is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Total number of thromboembolic events	0.29 (0.66)	0.54 (1.24)	0.49 (1.19)	0.36 (0.69)
Number of Transient Ischemic Attack (TIA)	0.05 (0.22)	0.19 (0.63)	0.06 (0.25)	0.03 (0.17)
Number of ischemic strokes	0.10 (0.30)	0.10 (0.30)	0.13 (0.35)	0.09 (0.34)
Number of haemorrhagic strokes	0.01 (0.07)	0.00 (0.00)	0.01 (0.08)	0.00 (0.00)
Number of embolism systemic	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	0.03 (0.17)
Number of deep vein thrombosis	0.01 (0.14)	0.05 (0.37)	0.01 (0.11)	0.00 (0.00)
Number of pulmonary embolisms	0.01 (0.07)	0.01 (0.12)	0.02 (0.13)	0.02 (0.12)
Number of stable anginas	0.02 (0.14)	0.00 (0.00)	0.02 (0.15)	0.02 (0.12)
Number of unstable anginas	0.01 (0.07)	0.01 (0.12)	0.12 (0.74)	0.02 (0.12)
Number of myocardial infarctions with ST segment elevation	0.04 (0.20)	0.12 (0.37)	0.07 (0.25)	0.05 (0.21)
Number of myocardial infarctions without ST segment elevation	0.05 (0.24)	0.07 (0.30)	0.06 (0.29)	0.12 (0.33)

35. Secondary Outcome

Title	Number of Patients With and Without Any History of Bleeding Events and Number of Patients in Each Category of Bleeding Type According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Number of patients with (category Yes) and without (category No) any history of bleeding events and number of patients in each category of the following bleeding types is reported: Intracranial Digestive Genitourinary Gingival Nasal Pulmonary Articular-muscular Conjunctival. Intracranial, digestive, genitourinary, gingival, nasal, pulmonary, articular-muscular, conjunctival were categorized in two categories: No Yes.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	177 92.2%	68 89.5%	120 72.3%	56 84.8%
Yes	14 7.3%	8 10.5%	46 27.7%	9 13.6%
No	188 97.9%	74 97.4%	158 95.2%	64 97%
Yes	3 1.6%	2 2.6%	7 4.2%	1 1.5%
No	183 95.3%	73 96.1%	140 84.3%	62 93.9%
Yes	8 4.2%	3 3.9%	26 15.7%	3 4.5%
No	189 98.4%	76 100%	158 95.2%	63 95.5%
Yes	2 1%	0 0%	6 3.6%	2 3%
No	191 99.5%	75 98.7%	163 98.2%	64 97%
Yes	0 0%	1 1.3%	2 1.2%	1 1.5%
No	191 99.5%	76 100%	157 94.6%	62 93.9%
Yes	0 0%	0 0%	8 4.8%	3 4.5%
No	191 99.5%	76 100%	162 97.6%	64 97%
Yes	0 0%	0 0%	3 1.8%	1 1.5%
No	189 98.4%	76 100%	162 97.6%	65 98.5%
Yes	2 1%	0 0%	3 1.8%	0 0%
No	191 99.5%	73 96.1%	164 98.8%	64 97%
Yes	0 0%	3 3.9%	1 0.6%	1 1.5%

36. Secondary Outcome

Title	Total Number of Bleeding Events and Number of Each Type of Bleeding Events According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Total number of bleeding events and number of bleeding events for the following bleeding types is reported: Intracranial Digestive Genitourinary Gingival Nasal Pulmonary Articular-muscular Conjunctival.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Number of total bleeding events	0.10 (0.42)	0.12 (0.36)	0.48 (1.01)	0.28 (0.82)
Number of intracranial events	0.02 (0.12)	0.03 (0.16)	0.04 (0.20)	0.02 (0.12)
Number of digestive events	0.06 (0.36)	0.04 (0.20)	0.27 (0.80)	0.06 (0.30)
Number of genitourinary events	0.01 (0.10)	0.00 (0.00)	0.04 (0.19)	0.06 (0.35)
Number of gingival events	0.00 (0.00)	0.01 (0.11)	0.01 (0.11)	0.03 (0.25)
Number of nasal events	0.00 (0.00)	0.00 (0.00)	0.07 (0.36)	0.08 (0.37)
Number of pulmonary events	0.00 (0.00)	0.00 (0.00)	0.02 (0.19)	0.02 (0.12)
Number of articular-muscular events	0.01 (0.10)	0.00 (0.00)	0.02 (0.19)	0.00 (0.00)
Number of conjunctival events	0.00 (0.00)	0.04 (0.20)	0.01 (0.08)	0.02 (0.12)

37. Secondary Outcome

Title	CHA2DS2-VASc Total Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The Congestive heart failure, Hypertension, Age (> 75), Diabetes mellitus, Stroke/TIA, Vascular disease, Age 65-74, Sex Category (CHA2DS2-VASc) score is a clinical prediction rule to estimate the risk of stroke in patients with Atrial Fibrillation (AF); it is frequently used to determine the need for an anticoagulation therapy, relating the high scores to a great risk of stroke and a low score corresponds to a lower risk of stroke. CHA2DS2-VASc stroke risk score may range from 0 to 9 with 0 being the best outcome.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Mean (Standard Deviation) [score on a scale]	4.05 (1.34)	4.43 (1.33)	4.63 (1.36)	4.32 (1.28)

38. Secondary Outcome

Title	Number of Patients on Each Category of CHA2DS2-VASc Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The Congestive heart failure, Hypertension, Age (> 75), Diabetes mellitus, Stroke/TIA, Vascular disease, Age 65-74, Sex Category (CHA2DS2-VASc) total score was categorized in three categories, according to the risk of stroke: Low risk (score 0 in male; score 1 in female) Moderate risk (score 1 in male; score 2 in female) High risk (score ≥2 in male; score ≥3 in female)
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Low risk	0 0%	0 0%	0 0%	0 0%
Moderate risk	0 0%	0 0%	0 0%	0 0%
High risk	192 100%	76 100%	166 100%	66 100%

39. Secondary Outcome

Title	HAS-BLED Total Score According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (>65 years), Drugs and Alcohol (HAS-BLED) score may range from 0 to 9 with 0 being the best outcome. The high scores indicate a greater risk of bleeding and a low score corresponds to a lower risk of bleeding.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Mean (Standard Deviation) [score on a scale]	1.99 (0.82)	1.64 (0.78)	2.01 (0.92)	2.06 (0.93)

40. Secondary Outcome

Title	Number of Patients in Each Category of HAS-BLED Score According to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	The Hypertension, Abnormal renal and liver function, Stroke (1 point), Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs and Alcohol (HAS-BLED) total score was categorized in three categories according to the bleeding risk: Low risk (score 0) Intermediate risk (score 1-2) High risk (score ≥3)
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Low risk	0 0%	0 0%	0 0%	0 0%
Intermediate risk	147 76.6%	64 84.2%	118 71.1%	48 72.7%
High risk	45 23.4%	12 15.8%	48 28.9%	18 27.3%

41. Secondary Outcome

Title	Number of Patients With Any Concomitant Treatments to Non-vitamin K Antagonist Oral Anticoagulant (NOAC) and Number of Patients for Each Concomitant Treatment to NOAC at Study Visit According to Current NOAC Type
Description	Number of patients in each category (No;Yes) of any concomitant treatments to NOAC and number of patients in each category (No; Yes) for each concomitant treatment to NOAC at study visit according to current NOAC type is reported. The concomitant treatment to non-vitamin K antagonist oral anticoagulant (NOAC) were the following: Angiotensin-Receptor Blockers (ARB) or Angiotensin Converting Enzyme inhibitors (ACE) inhibitor Beta-blocker Calcium channel blockers Diuretics Amiodarone Statin Proton pump inhibitor H2-receptor antagonist Digoxin NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) Dronedarone Ketoconazole Cyclosporine Itraconazole Other antiarrhythmics
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
No	0 0%	0 0%	0 0%	0 0%
Yes	192 100%	76 100%	166 100%	66 100%
No	54 28.1%	20 26.3%	57 34.3%	18 27.3%
Yes	138 71.9%	56 73.7%	109 65.7%	48 72.7%
No	82 42.7%	27 35.5%	54 32.5%	21 31.8%
Yes	110 57.3%	49 64.5%	112 67.5%	45 68.2%
No	154 80.2%	53 69.7%	136 81.9%	47 71.2%
Yes	38 19.8%	23 30.3%	30 18.1%	19 28.8%
No	87 45.3%	32 42.1%	56 33.7%	19 28.8%
Yes	105 54.7%	44 57.9%	110 66.3%	47 71.2%
No	174 90.6%	67 88.2%	146 88%	62 93.9%
Yes	18 9.4%	9 11.8%	20 12%	4 6.1%
No	83 43.2%	34 44.7%	77 46.4%	18 27.3%
Yes	109 56.8%	42 55.3%	89 53.6%	48 72.7%
No	89 46.4%	29 38.2%	58 34.9%	17 25.8%
Yes	103 53.6%	47 61.8%	108 65.1%	49 74.2%
No	191 99.5%	75 98.7%	162 97.6%	65 98.5%
Yes	1 0.5%	1 1.3%	4 2.4%	1 1.5%
No	168 87.5%	71 93.4%	153 92.2%	57 86.4%
Yes	24 12.5%	5 6.6%	13 7.8%	9 13.6%
No	180 93.8%	72 94.7%	155 93.4%	61 92.4%
Yes	12 6.3%	4 5.3%	11 6.6%	5 7.6%
No	192 100%	76 100%	163 98.2%	66 100%
Yes	0 0%	0 0%	3 1.8%	0 0%
No	192 100%	76 100%	166 100%	66 100%
Yes	0 0%	0 0%	0 0%	0 0%
No	192 100%	76 100%	166 100%	66 100%
Yes	0 0%	0 0%	0 0%	0 0%
No	192 100%	76 100%	166 100%	66 100%
Yes	0 0%	0 0%	0 0%	0 0%
No	188 97.9%	73 96.1%	160 96.4%	65 98.5%
Yes	4 2.1%	3 3.9%	6 3.6%	1 1.5%

42. Secondary Outcome

Title	Number of Patients in Each Category of Previous Vitamin K Antagonists (VKA) Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Number of patients in each category of previous Vitamin K Antagonists (VKA) treatment according to duration since the first non-vitamin K antagonist oral anticoagulant (NOAC) initiation is reported. Previous VKA treatment was categorized in 2 categories: No; Yes.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC)>4 months.
Measure Participants	39	461
No	26 13.5%	187 246.1%
Yes	13 6.8%	274 360.5%

43. Secondary Outcome

Title	Number of Patients Treated Previously With the VKA Acenocoumarol and Number of Patients Treated Previously With the VKA Warfarin According to Duration Since the First NOAC Initiation
Description	Number of patients treated previously (before they were treated with non-vitamin K antagonist oral anticoagulant (NOAC)) with the Vitamin K Antagonists (VKA) acenocoumarol and number of patients treated previously with the VKA warfarin according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who previously received VKA treatment. One patient received acenocoumarol and warfarin during the study, so the total percentage is not 100%.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	13	274
Acenocoumarol	13 6.8%	263 346.1%
Warfarin	0 0%	12 15.8%

44. Secondary Outcome

Title	Duration of Previous Vitamin K Antagonists (VKA) Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Duration of treatment (in years) is reported for: All patients treated previously with Vitamin K Antagonists (VKA) (row:All patients treated previously with VKA) Patients treated only with the VKA warfarin (row: Warfarin patients) Patients treated only with the VKA acenocoumarol (row: Acenocoumarol patients)
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	13	274
Acenocoumarol patients	3.65 (3.85)	3.88 (4.14)
Warfarin patients	3.35 (1.94)
All patients treated previously with VKA	3.65 (3.85)	3.87 (4.07)

45. Secondary Outcome

Title	Duration Since Non-valvular Atrial Fibrillation (NVAF) Diagnosis Until First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation According to Duration Since the First NOAC Initiation
Description	Duration (in years) since non-valvular atrial fibrillation (NVAF) diagnosis until first NOAC initiation according to duration since the first NOAC initiation is reported for: All patients Patients treated previously with VKA Patients treated only with NOAC as anticoagulant (AC)
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	460
All patients	1.62 (2.77)	3.27 (4.95)
Patients treated previously with VKA	3.71 (3.70)	4.84 (4.79)
Patients treated with NOAC as first AC	0.58 (1.30)	0.99 (4.27)

46. Secondary Outcome

Title	First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and First NOAC Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as first NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as first NOAC according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
First NOAC received: Dabigatran ( 110 mg BID and 150 mg BID patients)	23 12%	174 228.9%
First NOAC received: Rivaroxaban (15 mg QD and 20 mg QD patients)	2 1%	81 106.6%
First NOAC received: Apixaban (2.5 mg BID and 5 mg BID patients)	9 4.7%	143 188.2%
First NOAC received: Edoxaban (30 mg QD and 60 mg QD patients)	5 2.6%	63 82.9%
First NOAC dose: Dabigatran 110 mg BID	6 3.1%	88 115.8%
First NOAC dose: Dabigatran 150 mg BID	17 8.9%	86 113.2%
First NOAC dose: Rivaroxaban 15 mg QD	0 0%	30 39.5%
First NOAC dose: Rivaroxaban 20 mg QD	2 1%	51 67.1%
First NOAC dose: Apixaban 2.5 mg BID	4 2.1%	53 69.7%
First NOAC dose: Apixaban 5 mg BID	5 2.6%	90 118.4%
First NOAC dose: Edoxaban 30 mg QD	4 2.1%	26 34.2%
First NOAC dose: Edoxaban 60 mg QD	1 0.5%	37 48.7%

47. Secondary Outcome

Title	Number of Patients Who Changed (Increased and Decreased) and Did Not Change the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who changed (increased and decreased) and did not change the first non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.
Measure Participants	39	461
No	39 20.3%	427 561.8%
Yes (increase)	0 0%	8 10.5%
Yes (decrease)	0 0%	26 34.2%

48. Secondary Outcome

Title	First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation
Description	Treatment duration (in years) is reported for: Patients who stopped first NOAC treatment; Patients who did not stop the first NOAC treatment.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
Patients who stopped first NOAC treatment	0.01	1.60 (1.61)
Patients who did not stop the first NOAC treatment	0.30 (0.03)	2.38 (1.93)

49. Secondary Outcome

Title	Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation
Description	Reason for first NOAC treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Only patients who stopped first NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	1	42
Lack of effectiveness	0 0%	1 1.3%
Investigator's decision	0 0%	15 19.7%
Patient's decision	0 0%	7 9.2%
Adverse event	1 0.5%	19 25%

50. Secondary Outcome

Title	Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation
Description	Reason for first NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Only patients who changed dose in first NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	34
Lack of effectiveness	2 1%
Investigator's decision	24 12.5%
Patient's decision	0 0%
Adverse event	8 4.2%

51. Secondary Outcome

Title	Number of Switches to a New Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Per Patient According to Duration Since the First NOAC Initiation
Description	Number of switches to a new non-vitamin K antagonist oral anticoagulant (NOAC) per patient according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
Mean (Standard Deviation) [switches per patient]	0.03 (0.16)	0.10 (0.35)

52. Secondary Outcome

Title	Number of Patients in Each Category of Number of Switches to a New Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Per Patient According to Duration Since the First NOAC Initiation
Description	Number of patients based on the number of switches to a new NOAC per patient according to duration since the first NOAC initiation is reported. Number of switches to a new NOAC was categorized in 3 categories: 0 switches 1 switch 2 switches.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
0 switches	38 19.8%	419 551.3%
1 switch	1 0.5%	36 47.4%
2 switches	0 0%	6 7.9%

53. Secondary Outcome

Title	Total Number of Switches According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Total number of switches according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who switched to a new NOAC.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	1	48
Dabigatran to Rivaroxaban	0	3
Dabigatran to Apixaban	0	9
Dabigatran to Edoxaban	0	2
Rivaroxaban to Dabigatran	0	0
Rivaroxaban to Apixaban	1	10
Rivaroxaban to Edoxaban	0	2
Apixaban to Dabigatran	0	5
Apixaban to Rivaroxaban	0	3
Apixaban to Edoxaban	0	4
Edoxaban to Dabigatran	0	4
Edoxaban to Rivaroxaban	0	0
Edoxaban to Apixaban	0	6

54. Secondary Outcome

Title	Number of Switches in Each Category of Reason for Switch According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Reason for switch was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who switched to a new NOAC.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	1	48
Lack of effectiveness	0	1
Investigator's decision	0	17
Patient's decision	0	7
Adverse event	1	23

55. Secondary Outcome

Title	Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and Second NOAC Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as second NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as second NOAC according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Number of patients who stopped the first NOAC treatment and switched to a second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	1	42
Second NOAC received: Dabigatran (110 mg BID and 150 mg BID patients)	0 0%	8 10.5%
Second NOAC received: Rivaroxaban (15 mg QD and 20 mg QD patients)	0 0%	5 6.6%
Second NOAC received: Apixaban (2.5 mg BID and 5 mg BID patients)	1 0.5%	21 27.6%
Second NOAC received: Edoxaban (30 mg QD and 60 mg QD patients)	0 0%	8 10.5%
Second NOAC dose: Dabigatran 110 mg BID	6 3.1%
Second NOAC dose: Dabigatran 150 mg BID	2 1%
Second NOAC dose: Rivaroxaban 15 mg QD	3 1.6%
Second NOAC dose: Rivaroxaban 20 mg QD	2 1%
Second NOAC dose: Apixaban 2.5 mg BID	0 0%	13 17.1%
Second NOAC dose: Apixaban 5 mg BID	1 0.5%	8 10.5%
Second NOAC dose: Edoxaban 30 mg QD	3 1.6%
Second NOAC dose: Edoxaban 60 mg QD	5 2.6%

56. Secondary Outcome

Title	Number of Patients Who Changed (Increased or Decreased) and Did Not Change the Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who changed (increased or decreased) and did not change the second non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped the first NOAC treatment and switched to a second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	1	42
No	1 0.5%	40 52.6%
Yes (increase)	0 0%	1 1.3%
Yes (decrease)	0 0%	1 1.3%

57. Secondary Outcome

Title	Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation
Description	Second NOAC treatment duration (in years) according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months..
Measure Participants	0	6
Mean (Standard Deviation) [Years]	0.49 (0.39)

58. Secondary Outcome

Title	Number of Patients in Each Category of Reason for Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation
Description	Reason for second non-vitamin K antagonist oral anticoagulant (NOAC) treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	6
Lack of effectiveness	0 0%
Investigator's decision	2 1%
Patient's decision	0 0%
Adverse event	4 2.1%

59. Secondary Outcome

Title	Number of Patients in Each Category of Reason for Second Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation
Description	Reason for second NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who changed dose in second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	2
Lack of effectiveness	0 0%
Investigator's decision	2 1%
Patient's decision	0 0%
Adverse event	0 0%

60. Secondary Outcome

Title	Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Received and Third NOAC Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who received dabigatran, rivaroxaban, apixaban, edoxaban as third NOAC and number of patients who received dabigatran 110 mg BID (twice daily), dabigatran 150 mg BID, rivaroxaban 15 mg once daily (QD), rivaroxaban 20 mg QD, apixaban 2.5 mg BID, apixaban 5 mg BID, edoxaban 30 mg QD and edoxaban 60 mg QD as third NOAC according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped second NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	6
Third NOAC received: Dabigatran	1 0.5%
Third NOAC received: Rivaroxaban	1 0.5%
Third NOAC received: Apixaban	4 2.1%
Third NOAC received:Edoxaban	0 0%
Third NOAC dose: Dabigatran 110 mg BID	1 0.5%
Third NOAC dose: Dabigatran 150 mg BID	0 0%
Third NOAC dose: Rivaroxaban 15 mg QD	1 0.5%
Third NOAC dose: Rivaroxaban 20 mg QD	0 0%
Third NOAC dose: Apixaban 2.5 mg BID	3 1.6%
Third NOAC dose: Apixaban 5 mg BID	1 0.5%

61. Secondary Outcome

Title	Number of Patients Who Changed (Increased and Decreased) and Did Not Change the Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Dose According to Duration Since the First NOAC Initiation
Description	Number of patients who changed (increased and decreased) and did not change the third non-vitamin K antagonist oral anticoagulant (NOAC) dose according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who started third NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	6
No	6 3.1%
Yes (increase)	0 0%
Yes (decrease)	0 0%

62. Secondary Outcome

Title	Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Duration (in Years) According to Duration Since the First NOAC Initiation
Description	Duration of third NOAC treatment for patients who stopped NOAC treatment.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped third NOAC treatment. No patient stopped the third NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	0

63. Secondary Outcome

Title	Number of Patients in Each Category of Reason for Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Discontinuation According to Duration Since the First NOAC Initiation
Description	Reason for Third NOAC treatment discontinuation was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who stopped third NOAC treatment. No patient stopped the third NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	0
Lack of effectiveness
Investigator's decision
Patient's decision
Adverse event

64. Secondary Outcome

Title	Number of Patients in Each Category of Reason for Third Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment Change Dose According to Duration Since the First NOAC Initiation
Description	Reason for Third NOAC treatment change was categorized in four categories: Lack of effectiveness Investigator's decision Patient's decision Adverse event
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Participants of FAS who changed dose in third NOAC treatment. No patients stopped the third NOAC treatment.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	0	0
Lack of effectiveness
Investigator's decision
Patient's decision
Adverse event

65. Secondary Outcome

Title	Duration (in Years) in Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment According to Duration Since the First NOAC Initiation
Description	Duration (in years) in NOAC treatment is reported for: All patients (patients who received or did not receive VKA) Patients treated previously with Vitamin K Antagonists (VKA) Patients treated with NOAC as first anticoagulant
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
All patients	0.29 (0.03)	2.45 (1.96)
Patients treated previously with VKA	0.29 (0.03)	2.39 (1.98)
Patients treated with NOAC as first anticoagulant	0.29 (0.03)	2.54 (1.94)

66. Secondary Outcome

Title	Number of Patients in Each Category of Total Time in Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Treatment According to Duration Since the First NOAC Initiation
Description	Number of patients in each category of total time in non-vitamin K antagonist oral anticoagulant (NOAC) treatment according to duration since the first NOAC initiation is reported. Total time in NOAC treatment was categorized in 4 categories: <1 year; 1-2 years; 2-3 years; >3 years.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
<1 year	39 20.3%	149 196.1%
1-2 years	0 0%	87 114.5%
2-3 years	0 0%	74 97.4%
>3 years	0 0%	151 198.7%

67. Secondary Outcome

Title	Number of Patients for Each Type of Antiplatelet Treatment According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Number of patients for each type of following antiplatelet treatment that the patients ever received is reported: None (reports the patients who did not receive any antiplatelet treatment) Acetyl salicylic acid Clopidogrel Prasugrel Ticlopidine Ticagrelor Cilostazol Triflusal Dipyridamole Others (other antiplatelet treatment than above mentioned).
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
None (no antiplatelet treatment received)	35 18.2%	314 413.2%
Acetyl salicylic acid	4 2.1%	124 163.2%
Clopidogrel	1 0.5%	43 56.6%
Prasugrel	0 0%	2 2.6%
Ticlopidine	0 0%	1 1.3%
Ticagrelor	0 0%	1 1.3%
Cilostazol	0 0%	0 0%
Triflusal	0 0%	3 3.9%
Dipyridamole	0 0%	0 0%
Others (other antiplatelet treatment than listed above)	0 0%	0 0%

68. Secondary Outcome

Title	Number of Patients for Each Type of Antiplatelet Treatment at the Time of Study Visit According to Duration Since the First NOAC Initiation
Description	Number of patients for each of the following antiplatelet treatment types at the time of study visit according to duration since the first NOAC initiation is reported: None (reports the patients who did not receive any antiplatelet treatment) Acetyl salicylic acid Clopidogrel Prasugrel Ticlopidine Ticagrelor Cilostazol Triflusal Dipyridamole Others (other antiplatelet treatment than above mentioned).
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
None	38 19.8%	444 584.2%
Acetyl salicylic acid	0 0%	9 11.8%
Clopidogrel	1 0.5%	11 14.5%
Prasugrel	0 0%	0 0%
Ticlopidine	0 0%	0 0%
Ticagrelor	0 0%	1 1.3%
Cilostazol	0 0%	0 0%
Triflusal	0 0%	3 3.9%
Dipyridamole	0 0%	0 0%
Others	0 0%	0 0%

69. Secondary Outcome

Title	Time in Treatment With Antiplatelet Agents (in Years) According to Duration Since the First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Initiation
Description	Time in treatment with antiplatelet agents (in years) according to duration since the first NOAC initiation is reported.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	≤4 Months	>4 Months
Arm/Group Description	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) ≤4 months.	All patients who were on non-vitamin K antagonist oral anticoagulant (NOAC) >4 months.
Measure Participants	39	461
Mean (Standard Deviation) [Years]	5.82 (1.66)	5.98 (7.06)

70. Secondary Outcome

Title	Number of Patients in Each Score of Clinical Frailty Scale Grading at the Time of the Study Visit According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Clinical Frailty Scale (CFS) is used commonly to assess frailty. It is a 9-point scale from 1 to 9 (1=very fit; 2=well; 3=Managing well; 4=Vulnerable; 5=Mildly frail; 6=Moderately frail; 7=Severely frail; 8=very severely frail; 9=terminally ill) that summarizes the overall level of fitness or frailty of an older adult after they had been evaluated by a health care professional. Applying the CFS to patients is quick and requires data collection by watching the patient (mobilize), inquiring about their habitual physical activity and ability. A person with a score >4 was considered frail.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
1-Very fit	11 5.7%	6 7.9%	8 4.8%	0 0%
2-Well	24 12.5%	15 19.7%	18 10.8%	9 13.6%
3-Managing well	79 41.1%	23 30.3%	44 26.5%	24 36.4%
4-Vulnerable	45 23.4%	11 14.5%	46 27.7%	19 28.8%
5-Mildly frail	13 6.8%	8 10.5%	16 9.6%	7 10.6%
6-Moderately frail	15 7.8%	10 13.2%	24 14.5%	3 4.5%
7-Severely frail	4 2.1%	3 3.9%	9 5.4%	3 4.5%
8-Very severely frail	1 0.5%	0 0%	1 0.6%	1 1.5%
9-Terminally ill	0 0%	0 0%	0 0%	0 0%

71. Secondary Outcome

Title	Number of Patients in Each Category Clinical Frailty Scale at the Time of the Study Visit According to Current Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Type
Description	Clinical Frailty Scale (CFS) is used commonly to assess frailty. It is a 9-point scale from 1 to 9 (1=very fit; 2=well; 3=Managing well; 4=Vulnerable; 5=Mildly frail; 6=Moderately frail; 7=Severely frail; 8=very severely frail; 9=terminally ill) that summarizes the overall level of fitness or frailty of an older adult after they had been evaluated by a health care professional. Applying the CFS to patients is quick and requires data collection by watching the patient (mobilize), inquiring about their habitual physical activity and ability. CFS was categorized in two categories, according to this ranges: Frailty patients - CFS scoring >4 Non-frailty patients - CFS scoring ≤4
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	192	76	166	66
Non-frailty patients (CFS scoring ≤4)	159 82.8%	55 72.4%	116 69.9%	52 78.8%
Frailty patients (CFS scoring >4)	33 17.2%	21 27.6%	50 30.1%	14 21.2%

72. Secondary Outcome

Title	Number of Patients in Each Category of Reason for First Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Usage at the Time of First NOAC Initiation According to Current NOAC Type
Description	Reason for First NOAC usage was categorized in the following two categories: Primary prevention; Secondary prevention.
Time Frame	At the single study visit (Day 1).

Outcome Measure Data

Analysis Population Description

Full Analysis Set (FAS): All enrolled subjects who provided informed consent for this study and fulfilled all selection criteria. Only participants with non-missing outcomes were included in the analysis.

Arm/Group Title	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Arm/Group Description	Patients in this arm were on treatment with dabigatran (either were receiving 110 milligram (mg) dabigatran twice daily (BID) or 150 mg dabigatran BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with rivaroxaban (either were receiving 15 milligram (mg) rivaroxaban once daily (QD) or 20 mg rivaroxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Apixaban (either were receiving 2.5 milligram (mg) apixaban twice daily (BID) or 5 mg apixaban BID) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.	Patients in this arm were on treatment with Edoxaban (either were receiving 30 milligram (mg) edoxaban once daily (QD) or 60 mg edoxaban QD) at the time of study visit for their non-valvular atrial fibrillation (NVAF), according to the indication approved in their Summary of Product Characteristics (SmPC), and had initiated treatment with non-vitamin K antagonist oral anticoagulant (NOAC) at least 3 months before the study visit.
Measure Participants	190	75	166	66
Primary prevention	138 71.9%	61 80.3%	135 81.3%	54 81.8%
Secondary prevention	52 27.1%	14 18.4%	31 18.7%	12 18.2%

Adverse Events

Time Frame	Information about the adverse events (AEs) was collected from the patients' medical records at the time of single study visit (Day 1). AEs collection covered a total time of 10 years.
Adverse Event Reporting Description	Adverse events were collected and reported only for patients who received dabigatran either as first NOAC, or second NOAC or third NOAC.For rivaroxaban, apixaban and edoxaban patients' adverse events were not assessed.
Arm/Group Title	All Dabigatran Patients
Arm/Group Description	This group included all patients who received dabigatran either as first NOAC (patients who the first NOAC prescribed was dabigatran), or as second NOAC (patients who stopped the first prescribed NOAC and received dabigatran as second NOAC), or as third NOAC (patients who stopped the second prescribed NOAC and received dabigatran as third NOAC).
All Cause Mortality
	All Dabigatran Patients
	Affected / at Risk (%)	# Events
Total	0/206 (0%)
Serious Adverse Events
	All Dabigatran Patients
	Affected / at Risk (%)	# Events
Total	4/206 (1.9%)
Gastrointestinal disorders
Gastrointestinal haemorrhage	1/206 (0.5%)
Intestinal haemorrhage	1/206 (0.5%)
Lower gastrointestinal haemorrhage	1/206 (0.5%)
Nervous system disorders
Transient ischaemic attack	1/206 (0.5%)
Other (Not Including Serious) Adverse Events
	All Dabigatran Patients
	Affected / at Risk (%)	# Events
Total	0/206 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.